CompletedPhase 2

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

United States403 participantsStarted 2020-07-29

Plain-language summary

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: For the idiopathic pulmonary fibrosis (IPF) Cohort * Diagnosis of IPF within 7 years of screening * Female and males ≥ 40 years of age For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort * Evidence of progressive ILD within the 24 months before screening * Female and male ≥ 21 years of age. Exclusion Criteria: * Women of childbearing potential (WOCBP) * Active Smokers * Current malignancy or previous malignancy up to 5 years prior to screening * History of allergy to BMS-986278 or related compounds Other protocol-defined inclusion/exclusion criteria apply

What they're measuring

Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants

Timeframe: From baseline (first dose) up to week 26

Trial details

NCT IDNCT04308681

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-08-04

Results submitted2024-09-23

View on ClinicalTrials.gov More Pulmonary Fibrosis trials